|Cellebrite||HaMerkaz, Israel, Petah Tiqva|
|GLOBAL AGRINNO||Hungary, Vas, Vasvár|
|H&M CO:LAB||Stockholm, Stockholm County, Sweden|
|SK Materials||Seoul, Seoul-t'ukpyolsi, South Korea|
|Tennessee Community Ventures||Nashville, Tennessee, United States|
|Value Invest Korea (VIK)||Seoul, Seoul-t'ukpyolsi, South Korea|
|$25M||11 Nov 2022||Durham, North Carolina, United States|
|$20M||26 Sep 2022||Durham, North Carolina, United States|
|$45M||01 Aug 2022||Durham, North Carolina, United States|
|$120M||12 Apr 2022||Seattle, Washington, United States|
|$15M||23 Jun 2021||Germany, Bavaria, Germany|
Isotopen Technologien München
|$106M||22 Apr 2021||Germany, Bavaria, Germany|
|$7M||29 Dec 2020||Irvine, California, United States|
|$17M||13 Jan 2020||Irvine, California, United States|
|$15M||10 Oct 2019||Marlborough, Massachusetts, United States|
– Leukocare AG, a Martinsried/Munich, Germany and Milford, MA, USA-based biotechnology company specialized in the field of biopharmaceutical formulation development, closed a USD 17.5m (€14.6m) financing.
– The round was led by Petrichor Healthcare Capital Management with participation from existing shareholders.
– Proceeds will be used to accelerate Leukocare’s US expansion activities, bolster the company’s expertise in the fields of viral vector and vaccine formulation, as well as the emerging field of mRNA formulation, and to expand its suite of bioinformatics capabilities.
– ITM announced the successful close of a convertible loan financing totaling EUR 90 million (USD 109 million) led by Petrichor Healthcare Capital Management with participation of additional undisclosed investors.
– The proceeds will support the expansion of ITM’s precision oncology pipeline as well as fund late-stage development and market access activities for lead candidate, n.c.a. 177Lu-Edotreotide, currently in a phase III trial in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
– Further details of the financing were not disclosed.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.